Translating genomics in cancer care

Area of Science:

• Genomics and Personalized Medicine
• Oncology
• Health Technology Assessment

Background:

• Genomics is increasingly vital for personalized medicine, with oncology serving as a primary area for clinical translation.
• Genomic applications in oncology include hereditary cancer risk assessment (e.g., BRCA1/2) and somatic testing for treatment response (e.g., EGFR).
• Health technology assessment (HTA) is essential for evaluating new genomic technologies, considering clinical effectiveness, cost-effectiveness, and societal impact.

Purpose of the Study:

• To review evidentiary standards for translating cancer genomic technologies into clinical practice.
• To examine validity, utility, cost-effectiveness, health service impacts, and ethical/societal issues of genomic technologies.
• To identify research needs for the responsible integration of next-generation sequencing (NGS) in healthcare.

Main Methods:

• Systematic review of the evidentiary base for key cancer genomic technologies.
• Assessment of genomic technologies across the continuum of validity, utility, cost-effectiveness, and health services.
• Consideration of ethical and societal implications, including challenges from direct-to-consumer services and incidental findings.

Main Results:

• Significant evidentiary gaps persist in translating genomic technologies into routine clinical practice, particularly concerning efficacy and health outcomes.
• Next-generation sequencing (NGS) translation faces challenges including limited accuracy, unproven efficacy, and computational/counseling complexities.
• Current translation efforts for NGS often proceed despite these limitations, highlighting a need for rigorous evaluation.

Conclusions:

• Substantial research is required to address efficacy, cost-effectiveness, and health services impacts for genomic technologies in cancer care.
• Responsible introduction of NGS into healthcare necessitates further research to ensure effective, efficient, and equitable application.
• Addressing evidentiary gaps is critical for the successful and ethical integration of genomics into routine cancer diagnostics and therapeutics.